Hope for Cancer Patients ! Propanc Pancreatic Treatment Meets FDA Milestone .

Cancer patients with pancreatic, ovarian, or colorectal tumors have reason for hope. A solid tumor treatment known as PRP, developed by Propanc Biopharma Inc. (PPCB), has received an Orphan Drug Designation from the U.S. Food & Drug Administration as the company prepares to move forward into first-in-human studies.

PRP is an intravenous solution designed for once-daily administration. The product contains a combination of two pancreatic proenzymes, trypsinogen and chymotrypsinogen, for the treatment of pancreatic cancer, which currently has an average survival rate of 6 months, and fewer than 5 percent of patients survive for 5 years after diagnosis.

Loading...
Copy
READ  breast cancer

One thought on “Hope for Cancer Patients ! Propanc Pancreatic Treatment Meets FDA Milestone .

Leave a Reply

Pin It on Pinterest